The DOI matches its Crossref record; 81 of the 88 references it cites were found in a registry or an index.
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Open accessAbstract
Glioblastoma multiforme (GBM) is a devastating disease and the most lethal of adult brain tumors. Treatment is based on surgery, radiotherapy and chemotherapy by oral temozolomide (TMZ), which is the most potent chemotherapy agent for the treatment of GBM. Despite TMZ efficiency, the prognosis of these tumors remains poor. This is because of inherent or acquired resistance of glioma tumor cells to TMZ. This resistance is caused by DNA repair enzyme activity, overexpression of epidermal growth factor receptor (EGFR), galectin-1, murine double minute 2 (Mdm2), p53 and phosphatase and tensin homolog (PTEN) mutations. Many strategies to overcome this resistance have been developed. In this review, we will describe the main mechanisms of GBM resistance to TMZ and different strategies developed to reverse the phenotype of these tumor cells. Finally, we will discuss the drawbacks and limitations of these strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
Wood, R., Mitchell, M., Sgouros, J., & Lindahl, T. (2001) · Science · doi:10.1126/science.1056154 · Cited by 1,719
Galectins as modulators of tumour progression
Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339
Cited by
Sorted by citations
Items 201–238 of 238
Pérez-Aliacar, M., Ayensa-Jiménez, J., Ranđelović, T., Ochoa, I., & Doblaré, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.24.568421 · Cited by 2
Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003–2023)
Yu, S., Wu, J., Jing, Y., Lin, P., Lang, L., Xiong, Y., Chen, W., Liu, W., Sun, C., & Lu, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1539937 · Cited by 1
Sol-Gel Technologies for Drug Delivery in Potential Cancer Treatments
Druzian, D. M., Silva, M. D. C. D., da Silva, W. L., & dos Santos, J. H. Z. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_397 · Cited by 1
3D Conformal Re-Irradiation with Temozolamide for Recurrent Glioblastoma: A Prospective Cohort Study
Eladawei, G. E., & Abdellatif, R. M. (2019) · Journal of Cancer Therapy · doi:10.4236/jct.2019.108051 · Cited by 1
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells
Chen, Y., Tseng, B.-J., Tsai, Y., & Tseng, S. (2020) · Anticancer Research · doi:10.21873/anticanres.14517 · Cited by 1
RetractedWNT vampirization by glioblastoma leads to tumor growth and neurodegeneration
Portela-Esteban, M., Venkataramani, V., Fahey-Lozano, N., Seco, E., Losada‐Pérez, M., Winkler, F., & Casas‐Tintó, S. (2018) · Figshare · doi:10.26181/6004ef260c4d4 · Cited by 1
Molecular mechanisms in temozolomide-resistant glioblastoma
Lee, S. Y., & Kitange, G. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00029-4 · Cited by 1
Godugu, K., Hay, B. A., Glinsky, G. V., & Mousa, S. A. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac180 · Cited by 1
Sol-Gel Technologies for Drug Delivery in Potential Cancer Treatments
Druzian, D. M., Silva, M. D. C. D., da Silva, W. L., & dos Santos, J. H. Z. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_397-1 · Cited by 1
BIOMARKERS FOR EARLY DIAGNOSTICS OF BRAIN TUMORS
Medyanik, I. A., GORDETSOV, A. S., Сергеевич, Я. К., Krasnikova, O. V., Frayerman, Shenkarev, Z. O., & Karyakin, N. N. (2021) · Practical oncology · doi:10.31917/2201087 · Cited by 1
Swift Formation Of Optimal Single Spheroids Towards In-Vitro 3-Dimensional Tumour ModelsPreprint
Habra, K., Pearson, J. R. D., & McArdle, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1365421/v1 · Cited by 1
Analysis of Histone Deacetylase-Dependent Effects on Cell Migration Using the Stripe Assay
Mertsch, S., & Thanos, S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_5
Metformin as a potential therapy for malignant astrocytoma
Eagles, L. (2018) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton)
Prolactin-Secreting Pituitary Adenomas: Clinical Management
Faje, A. T., Zachariah, M. A., & Swearingen, B. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_8
Tang, Q. (2019) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-tang-qi-2019
Areeb, Z. (2020) · Minerva Access (University of Melbourne)
Jermakowicz, A. M., Kurimchak, A., Sarkaria, J. N., Komotar, R. J., Ivan, M. E., Schürer, S. C., Duncan, J. S., & Ayad, N. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.21.306910
Nanopolymeric systems to improve brain cancer treatment outcomes
Reinhardt, L. S., Dias, M. C. H. D. B., Arantes, P. R., Henn, J. G., Nugent, M., & Moura, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820043-8.00001-3
Prognostic and Clinical Values of Chaperone Protein P4HB in Malignant GliomaPreprint
Sun, S., Kiang, K. M. Y., & Leung, G. (2021) · Research Square · doi:10.21203/rs.3.rs-808854/v1
Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour ModelsPreprint
Habra, K., Pearson, J. R. D., & McArdle, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472941
Urcuyo, J. C., Massey, S. C., Hawkins-Daarud, A. J., Marin, B. M., Burgenske, D. M., Sarkaria, J. N., & Swanson, K. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471540
Gheidari, F., Arefian, E., Kabiri, M., Seyedjafari, E., Teimoori‐Toolabi, L., & Soleimani, M. (2021) · Research Square · doi:10.21203/rs.3.rs-186982/v1
Zastrow, J. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9320
Sun, Z., Zeng, F., Liu, Y., Ouyang, Q., Tan, J., Li, X., Mei, C., Liu, Z., & Liu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2206400/v1
Kubiak, K. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9838
Zhang, X., Huang, D., Liang, M., Ruan, Z., Xu, Y., Qiu, Z., & Chen, X. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100488
RetractedUso de los flavonoides en modelos experimentales de glioblastoma multiforme
del Tolima, U., Arzuza, J. P. A., Gil, A. P. R., de Peloponneso, U., Turner, L. F., & del Tolima, U. (2025) · Actualidades Biológicas · doi:10.17533/udea.acbi/v47n123a09
Teng, X.-Q., Wang, Y., Qu, Q., Xu, W.-X., Zhuang, H., Wei, Y., Dai, Y., & Qu, J. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.105
Xue, B.-Z., Xiang, W., Zhang, Q., Wang, H.-F., Zhou, Y.-J., Tian, H., Abdelmaksou, A., Xue, J., Sun, M.-X., Yi, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978244
Diller, E. E., Cao, S., Ey, B., Lober, R. M., & Parker, J. G. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1908.02334
Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways
Sani, S. (2020) · theses.fr (ABES) · doi:10.70675/9566c585z0508z455bz9064z6bb61435b210
Wang, J., Xing, Y., Zhao, X., Cao, Y., Zheng, N., Wang, W., & Zhou, L. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07249-1
Circular RNA serves as an upstream regulator of the miRNA//ABCC1 axis in human cancers
Zou, Q., & Yang, X. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109054
Raloxifene suppresses growth and promotes intrinsic apoptotic signaling in C6 glioma cells
Roustaei, M., Pournajaf, S., & Shalmani, L. M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05792-x
Metadata
- Authors
- Messaoudi, K., Clavreul, A., & Lagarce, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Lagarce, Frédéric
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 20
- Issue
- 7
- Pages
- 899-905
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2019154144
- Cited by
- 238
- References
- 88
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 19 · 2023: 22 · 2022: 21 · 2021: 27 · 2020: 42 · 2019: 25 · 2018: 29 · 2017: 23 · 2016: 16 · 2015: 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- Ligue contre le Cancer, Comité du Maine et Loire, France
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, temozolomide, drug resistance, DNA repair, EGFR overexpression, galectin-1, MDM2, p53, PTEN mutation, resistance reversal strategies, brain tumors
- MeSH terms
- Temozolomide, Animals, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Phenotype, Structure-Activity Relationship, Biomarkers, Tumor, Drug Design, Molecular Structure, Signal Transduction, Antineoplastic Agents, Alkylating, Drug Resistance, Neoplasm, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
